98 related articles for article (PubMed ID: 15207551)
1. New surface-active polymers for ophthalmic formulations: evaluation of ocular tolerance.
Baydoun L; Furrer P; Gurny R; Müller-Goymann CC
Eur J Pharm Biopharm; 2004 Jul; 58(1):169-75. PubMed ID: 15207551
[TBL] [Abstract][Full Text] [Related]
2. W/O microemulsions for ocular delivery: evaluation of ocular irritation and precorneal retention.
Alany RG; Rades T; Nicoll J; Tucker IG; Davies NM
J Control Release; 2006 Mar; 111(1-2):145-52. PubMed ID: 16426694
[TBL] [Abstract][Full Text] [Related]
3. Ophthalmic formulations of the intraocular hypotensive melatonin agent 5-MCA-NAT.
Andrés-Guerrero V; Alarma-Estrany P; Molina-Martínez IT; Peral A; Herrero-Vanrell R; Pintor J
Exp Eye Res; 2009 Mar; 88(3):504-11. PubMed ID: 19056382
[TBL] [Abstract][Full Text] [Related]
4. Formulation and in vitro evaluation of cysteamine hydrochloride viscous solutions for the treatment of corneal cystinosis.
Bozdağ S; Gümüş K; Gümüş O; Unlü N
Eur J Pharm Biopharm; 2008 Sep; 70(1):260-9. PubMed ID: 18590953
[TBL] [Abstract][Full Text] [Related]
5. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance.
Enríquez de Salamanca A; Diebold Y; Calonge M; García-Vazquez C; Callejo S; Vila A; Alonso MJ
Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1416-25. PubMed ID: 16565375
[TBL] [Abstract][Full Text] [Related]
6. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
[TBL] [Abstract][Full Text] [Related]
7. Study of the preparation of sustained-release microspheres containing zedoary turmeric oil by the emulsion-solvent-diffusion method and evaluation of the self-emulsification and bioavailability of the oil.
You J; Cui FD; Han X; Wang YS; Yang L; Yu YW; Li QP
Colloids Surf B Biointerfaces; 2006 Mar; 48(1):35-41. PubMed ID: 16480856
[TBL] [Abstract][Full Text] [Related]
8. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide.
Vandamme TF; Brobeck L
J Control Release; 2005 Jan; 102(1):23-38. PubMed ID: 15653131
[TBL] [Abstract][Full Text] [Related]
9. Ocular tolerance of absorption enhancers in ophthalmic preparations.
Furrer P; Mayer JM; Plazonnet B; Gurny R
AAPS PharmSci; 2002; 4(1):E2. PubMed ID: 12049486
[TBL] [Abstract][Full Text] [Related]
10. Prediction of eye irritation potential of surfactant-based rinse-off personal care formulations by the bovine corneal opacity and permeability (BCOP) assay.
Cater KC; Harbell JW
Cutan Ocul Toxicol; 2006; 25(3):217-33. PubMed ID: 16980247
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of ophthalmic suspensions using surface tension.
Yasueda S; Inada K; Matsuhisa K; Terayama H; Ohtori A
Eur J Pharm Biopharm; 2004 Mar; 57(2):377-82. PubMed ID: 15018999
[TBL] [Abstract][Full Text] [Related]
12. A topical w/o/w multiple emulsions prepared with Tetronic 908 as a hydrophilic surfactant: formulation, characterization and release study.
Tirnaksiz F; Kalsin O
J Pharm Pharm Sci; 2005 Aug; 8(2):299-315. PubMed ID: 16124940
[TBL] [Abstract][Full Text] [Related]
13. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application.
Agnihotri SM; Vavia PR
Nanomedicine; 2009 Mar; 5(1):90-5. PubMed ID: 18823824
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats.
Wang S; Li D; Ito Y; Nabekura T; Wang S; Zhang J; Wu C
Curr Eye Res; 2004 Jul; 29(1):51-8. PubMed ID: 15370367
[TBL] [Abstract][Full Text] [Related]
15. [The deleterious effect of certain surface active agents on the ocular surface].
Ravet O
Bull Soc Belge Ophtalmol; 2007; (304):145-9. PubMed ID: 17718239
[TBL] [Abstract][Full Text] [Related]
16. Extent of corneal injury as a biomarker for hazard assessment and the development of alternative models to the Draize rabbit eye test.
Jester JV
Cutan Ocul Toxicol; 2006; 25(1):41-54. PubMed ID: 16702053
[TBL] [Abstract][Full Text] [Related]
17. In vivo ocular availability of ketorolac following ocular instillations of aqueous, oil, and ointment formulations to normal corneas of rabbits: a technical note.
Malhotra M; Majumdar DK
AAPS PharmSciTech; 2005 Oct; 6(3):E523-6. PubMed ID: 16354013
[TBL] [Abstract][Full Text] [Related]
18. Topical delivery of lipophilic drugs from o/w Pickering emulsions.
Frelichowska J; Bolzinger MA; Pelletier J; Valour JP; Chevalier Y
Int J Pharm; 2009 Apr; 371(1-2):56-63. PubMed ID: 19135516
[TBL] [Abstract][Full Text] [Related]
19. [Preparation and in vitro corneal retention behavior of novel cationic microemulsion/in situ gel system].
Ma SW; Gan Y; Gan L; Zhu CL; Zhu JB
Yao Xue Xue Bao; 2008 Jul; 43(7):749-55. PubMed ID: 18819481
[TBL] [Abstract][Full Text] [Related]
20. New tools for the evaluation of toxic ocular surface changes in the rat.
Pauly A; Brignole-Baudouin F; Labbé A; Liang H; Warnet JM; Baudouin C
Invest Ophthalmol Vis Sci; 2007 Dec; 48(12):5473-83. PubMed ID: 18055795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
